Analysts Expect Regulus Therapeutics Inc. (NASDAQ:RGLS) to Post -$0.05 Earnings Per Share

Wall Street brokerages predict that Regulus Therapeutics Inc. (NASDAQ:RGLS – Get Rating) will announce earnings per share of ($0.05) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Regulus Therapeutics’ earnings. Regulus Therapeutics reported earnings per share of ($0.08) during the same quarter last year, which suggests a positive year over year growth rate of 37.5%. The firm is scheduled to issue its next earnings report after the market closes on Monday, January 1st.

On average, analysts expect that Regulus Therapeutics will report full year earnings of ($0.22) per share for the current year, with EPS estimates ranging from ($0.25) to ($0.19). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that that provide coverage for Regulus Therapeutics.

Regulus Therapeutics (NASDAQ:RGLS – Get Rating) last posted its quarterly earnings data on Thursday, March 10th. The biopharmaceutical company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). During the same period in the previous year, the company earned ($0.03) earnings per share.

Several research firms have recently weighed in on RGLS. Zacks Investment Research lowered shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 16th. HC Wainwright reiterated a “buy” rating and set a $2.00 price objective on shares of Regulus Therapeutics in a report on Tuesday, January 25th. Finally, StockNews.com assumed coverage on Regulus Therapeutics in a research note on Thursday. They issued a “sell” rating for the company.

Several institutional investors have recently added to or reduced their stakes in the business. DAFNA Capital Management LLC bought a new position in shares of Regulus Therapeutics in the fourth quarter valued at approximately $1,750,000. Asymmetry Capital Management L.P. boosted its holdings in Regulus Therapeutics by 94.9% during the 4th quarter. Asymmetry Capital Management L.P. now owns 2,731,044 shares of the biopharmaceutical company’s stock worth $860,000 after acquiring an additional 1,329,553 shares during the last quarter. Morgan Stanley boosted its holdings in Regulus Therapeutics by 206.0% during the 2nd quarter. Morgan Stanley now owns 499,625 shares of the biopharmaceutical company’s stock worth $406,000 after acquiring an additional 336,374 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of Regulus Therapeutics by 13.8% in the 3rd quarter. Geode Capital Management LLC now owns 670,747 shares of the biopharmaceutical company’s stock worth $463,000 after acquiring an additional 81,551 shares in the last quarter. Finally, Commonwealth Equity Services LLC raised its holdings in shares of Regulus Therapeutics by 38.8% in the third quarter. Commonwealth Equity Services LLC now owns 111,000 shares of the biopharmaceutical company’s stock valued at $76,000 after purchasing an additional 31,000 shares during the last quarter. 47.06% of the stock is currently owned by hedge funds and other institutional investors.

Shares of RGLS opened at $0.17 on Monday. The firm has a market cap of $25.11 million, a PE ratio of -0.52 and a beta of 2.21. Regulus Therapeutics has a 52-week low of $0.17 and a 52-week high of $1.48. The business’s 50 day moving average price is $0.26 and its two-hundred day moving average price is $0.31. The company has a debt-to-equity ratio of 0.09, a quick ratio of 12.48 and a current ratio of 12.48.

Regulus Therapeutics Company Profile (Get Rating)

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

Further Reading